MC# 17-17 - A Phase I Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

  • Agent(s): RGX-104
  • Disease Type(s): Lung-NSCLC, Ovarian, Neuroendocrine, Breast, Head and Neck, Renal, Lung-SCLC, Bladder
  • Phase(s): I
  • Drug Classification(s): Targeted Therapy, Small Molecule
  • Molecular Target(s): LXR, ApoE

Mechanism of Action

RGX-104 is a potent small molecule Liver X receptor (LXR) agonist with a higher affinity for the LXRβ isoform.  LXRβ activation results in expression of Apolipoprotein E (ApoE), which regulates three suppressive tumorigenic features – suppression of cancer cell invasion, suppression of angiogenesis, and enhancement of tumoral immune response.  Collectively, activation of ApoE expression results in inhibition of primary tumor growth and metastatic spread.

Purpose

In this study, the sponsor and investigators want to learn:

  • The effects of RGX-104
  • How much RGX-104 is absorbed into the blood and how fast it is removed
  • How proteins that indicate the status of  disease are affected with use of RGX-104
  • If RGX-104 prevents or delays tumor growth or shrinks an existing tumor
Inclusion Criteria
  • The patient must have histologic or cytologic evidence of a malignant solid tumor or lymphoma (any histology) and must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy likely to result in clinical benefit.
  • The patient must have advanced disease, defined as cancer that is either metastatic or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
  • The patient must have disease that is measurable by standard imaging techniques (excluding patients with prostate cancer with PSA > 2 and bone disease documented by bone scan or other imaging), per immune-related response criteria (irRC; all tumor types except lymphoma) or International Working Group (IWG) response revised criteria for malignant lymphoma (lymphoma only). For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field(s), unless disease progression has been documented at that disease site subsequent to radiation.
  • The patient is ≥18 years old.
  • The patient has an ECOG PS of ≤1.
  • The patient has adequate baseline organ function, as demonstrated by the following:
    • Serum creatinine ≤1.5 times institutional upper limit of normal (ULN) or calculated creatinine clearance >30 mL/min;
    • Serum albumin ≥2.5 g/dl;
    • Bilirubin ≤1.5 institutional ULN;
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5  institutional ULN (patients with hepatic metastases must have AST/ALT ≤5 times ULN);
    • For patients not taking warfarin: international normalized ratio (INR) ≤1.5 or prothrombin time (PT) ≤1.5 ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≤1.5 ULN. For patients taking warfarin: INR <3.5.
  • The patient has adequate baseline hematologic function, as demonstrated by the following:
    • Absolute neutrophil count (ANC) ≥1.5x109/L
    • Hemoglobin ≥8 g/dL and no red blood cell (RBC) transfusions during the prior 14 days
    • Platelet count ≥100x109/L and no platelet transfusions during the prior 14 days
  • The patient has a normal left ventricular ejection fraction (LVEF) per institutional criteria as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scanning.
  • If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 2 weeks prior to treatment.
  • The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 1 month after the last treatment with RGX-104.
  • The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  • The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
  • Tumor tissue (a minimum of 5 and up to 10 unstained slides, or paraffin block), ideally from the patient’s most recent biopsy, must be delivered from the patient’s local institution to the site prior to treatment with RGX-104.
Exclusion Criteria
  • The patient has persistent clinically significant toxicities (Grade ≥2) from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy and alopecia which are permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).
  • The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 14 days prior to RGX-104 administration (42 days for prior nitrosourea or mitomycin-C; patients with advanced prostate cancer who are receiving luteinizing hormone releasing hormone (LHRH) agonists are permitted onto the study and should continue use of these agents during study treatment).
  • The patient has received treatment with an investigational systemic anticancer agent within 14 days prior to RGX-104 administration.
  • The patient has previously received treatment with RGX-104 or another investigational agent that is a known LXR agonist.
  • The patient has an additional active malignancy that may confound the assessment of the study endpoints. Patients with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia, and melanoma in sutu), organ-confined prostate cancer with no evidence of progressive disease.
  • The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure (see Appendix 1), uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  • The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.
  • The patient has known active or suspected brain or leptomeningeal metastases (central nervous system [CNS] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Patients with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 2 months following radiation therapy or other locoregional ablative therapy to the CNS.
  • The patient has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to RGX-104 administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • The patient is pregnant or breast feeding.
  • The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
  • The patient is oxygen-dependent.
  • The patient has a history of pancreatitis.
  • The patient has Grade ≥2 hypercholesterolemia (total cholesterol >300 mg/dL or >7.75 mmol/L) and/or hypertriglyceridemia (triglyceride >300 mg/dL or >3.42 mmol/L) in the fasting state.
  • QTcF >450 msec (males) or >470 msec (females).
  • The patient requires statin (e.g., rosuvastatin, atorvastatin, etc.) therapy.
  • The patient requires treatment with a medication that is a strong inhibitor of CYP3A4 (boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole).
  • For the nivolumab combination expansion stage, patients with BC who have disease that is considered to be Her-2/neu-overexpressing (i.e. overexpressing the human epidermal growth factor receptor 2 tyrosine kinase or demonstrating amplification of  > 2 gene copies by FISH analysis.)
  • For the docetaxel escalation and expansion stages, patients with NSCLC with alkaline phosphatase > 2.5 x institutional ULN and AST or ALT > 1.5 x institutional ULN.
  • The patient has clinical or laboratory evidence of a paraneoplastic syndrome.
  • The patient has experienced weight loss of >10% of their body weight over the preceding 3 months.
  • The patient requires treatment with a pH elevating agent, including H2 blockers, proton pump inhibitors, and antacids. If the medication is considered to be medically necessary, the patient should be discussed with the Medical Monitor.
  • The patient has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.

Location

  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info: https://clinicaltrials.gov/ct2/show/NCT02922764?term=RGX-104-001&rank=1

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 17-17